Total Payments
$8,826
2024 Payments
$1,417
Companies
24
Transactions
355
Medicare Patients
1,868
Medicare Billing
$262,655
Payment Breakdown by Category
Food & Beverage$8,711 (98.7%)
Other$68.77 (0.8%)
Education$31.32 (0.4%)
Travel$14.95 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,711 | 346 | 98.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $68.77 | 4 | 0.8% |
| Education | $31.32 | 4 | 0.4% |
| Travel and Lodging | $14.95 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $2,537 | 70 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $1,479 | 66 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $1,195 | 65 | $0 (2024) |
| Adamas Pharmaceuticals, Inc. | $822.76 | 42 | $0 (2021) |
| Nevro Corp. | $359.71 | 6 | $0 (2018) |
| GE HealthCare | $305.84 | 17 | $0 (2023) |
| Amneal Pharmaceuticals LLC | $289.63 | 14 | $0 (2023) |
| CATALYST PHARMACEUTICALS, INC. | $277.24 | 15 | $0 (2024) |
| Eisai Inc. | $272.56 | 9 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $172.43 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,417 | 73 | UCB, Inc. ($416.91) |
| 2023 | $742.31 | 29 | UCB, Inc. ($289.49) |
| 2022 | $1,755 | 62 | Neurocrine Biosciences, Inc. ($590.50) |
| 2021 | $933.40 | 42 | UCB, Inc. ($405.44) |
| 2020 | $914.33 | 40 | UCB, Inc. ($316.63) |
| 2019 | $1,400 | 53 | UCB, Inc. ($411.72) |
| 2018 | $1,438 | 43 | ACADIA Pharmaceuticals Inc ($474.51) |
| 2017 | $225.06 | 13 | ACADIA Pharmaceuticals Inc ($77.01) |
All Payment Transactions
355 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.37 | General |
| Category: Neuropsychiatry | ||||||
| 12/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $4.69 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $3.93 | General |
| Category: Neuropsychiatry | ||||||
| 12/13/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $28.40 | General |
| Category: Neurology | ||||||
| 12/09/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $31.28 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $1.06 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $0.92 | General |
| Category: Neuropsychiatry | ||||||
| 11/22/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $121.87 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Merz Pharmaceuticals, LLC | INBRIJA (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Parkinson's Disease | ||||||
| 11/19/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $3.31 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/18/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $55.82 | General |
| Category: Neurology | ||||||
| 11/18/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $9.23 | General |
| Category: Neurology | ||||||
| 11/08/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $29.16 | General |
| Category: Neurology | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.40 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $4.06 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $3.60 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: Neuropsychiatry | ||||||
| 10/23/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/18/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: Neurology | ||||||
| 10/16/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $21.55 | General |
| Category: NEUROLOGY | ||||||
| 10/16/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Education | Cash or cash equivalent | $16.72 | General |
| Category: NEUROLOGY | ||||||
| 10/16/2024 | CATALYST PHARMACEUTICALS, INC. | FYCOMPA (Drug) | Food and Beverage | Cash or cash equivalent | $6.08 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 441 | 819 | $119,310 | $62,885 |
| 2022 | 11 | 498 | 916 | $139,290 | $76,006 |
| 2021 | 11 | 530 | 930 | $133,400 | $74,488 |
| 2020 | 10 | 399 | 793 | $107,040 | $49,276 |
Total Patients
1,868
Total Services
3,458
Medicare Billing
$262,655
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 99 | 220 | $33,000 | $16,132 | 48.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 46 | 46 | $20,700 | $14,250 | 68.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $15,900 | $7,512 | 47.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 69 | $12,420 | $7,075 | 57.0% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 30 | 34 | $9,350 | $4,913 | 52.5% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 17 | 22 | $7,150 | $4,849 | 67.8% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 24 | 51 | $7,800 | $2,591 | 33.2% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 14 | 17 | $2,550 | $1,744 | 68.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2023 | 28 | 31 | $3,100 | $1,567 | 50.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 17 | 17 | $3,400 | $1,449 | 42.6% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 27 | 135 | $2,700 | $699.57 | 25.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 27 | 124 | $1,240 | $104.06 | 8.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 69 | 69 | $31,050 | $21,369 | 68.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 128 | 284 | $42,600 | $21,194 | 49.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 58 | 58 | $17,400 | $8,468 | 48.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 65 | $11,700 | $7,061 | 60.4% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 42 | 45 | $12,375 | $6,783 | 54.8% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2022 | 12 | 15 | $4,875 | $3,396 | 69.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 23 | 45 | $6,750 | $2,605 | 38.6% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Office | 2022 | 42 | 45 | $4,500 | $2,429 | 54.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 20 | 20 | $4,000 | $1,868 | 46.7% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2022 | 21 | 134 | $2,680 | $715.71 | 26.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 30 | 136 | $1,360 | $117.10 | 8.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 125 | 263 | $38,380 | $20,311 | 52.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 83 | 83 | $22,850 | $11,993 | 52.5% |
About Dr. Eugenio Guevara, M.D
Dr. Eugenio Guevara, M.D is a Interventional Pain Medicine healthcare provider based in Hialeah, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/17/2007. The National Provider Identifier (NPI) number assigned to this provider is 1033305701.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eugenio Guevara, M.D has received a total of $8,826 in payments from pharmaceutical and medical device companies, with $1,417 received in 2024. These payments were reported across 355 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($8,711).
As a Medicare-enrolled provider, Guevara has provided services to 1,868 Medicare beneficiaries, totaling 3,458 services with total Medicare billing of $262,655. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Other Specialties Neurology
- Location Hialeah, FL
- Active Since 09/17/2007
- Last Updated 04/22/2019
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1033305701
Products in Payments
- Briviact (Drug) $1,821
- NUPLAZID (Drug) $1,479
- INGREZZA (Drug) $1,039
- GOCOVRI (Drug) $822.76
- Vimpat (Drug) $715.17
- Senza Spinal Cord Stimulation System (Device) $359.71
- RYTARY (Drug) $289.63
- FYCOMPA (Drug) $255.21
- AUSTEDO (Drug) $172.43
- Dhivy (Drug) $157.58
- Ongentys (Drug) $155.54
- INBRIJA (Drug) $154.61
- NOURIANZ (Drug) $154.16
- Leqembi (Drug) $150.27
- LYRICA (Drug) $128.06
- Fycompa (Drug) $104.11
- Spritam (Drug) $98.28
- LEQEMBI (Drug) $76.60
- DaTscan (Drug) $61.71
- OXTELLAR XR (Drug) $45.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.